SAN DIEGO – Drugmakers are racing to be the first to market an oral version of the newest class of weight-loss drugs that has exploded in popularity in the past year.
The results of two clinical trials, presented here at the 2023 American Diabetes Association Scientific Sessions, point to the progress pharmaceutical companies have made in developing a weight-loss drug in pill form.
Popular drugs, including Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy, can produce significant weight loss, but all are given as weekly injections.
A daily pill form of weight loss medication may be a more palatable option for some people.
“The great thing about tablets is that pretty much everyone is used to taking a tablet for something, even if it’s just a vitamin. It’s not a big deal,” said Dr. Robert Gabbay, ADA’s chief scientist.
For more information visit nbcnews.com.
